Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group's pharmaceutical business for more than $3 billion, a deal that would allow the Japanese company to focus on its key chemical businesses.

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

With a growing footprint in health-care analytics and digital transformation, global consulting powerhouse ZS Associates is ramping up its presence in Jamaica, betting on the island’s talent pool to ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

The battle to drastically reduce, if not totally eradicate, dengue cases must involve yearlong efforts. It cannot be a ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...

The Boston area began 2025 with a record-high office vacancy rate of 17%. Yet there are at least seven notable office ...